Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Business

The Medicines Company to Participate in the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference


Print article Print article
Refer this article Refer to a friend
© Business Wire 2008
2008-06-05 23:47:27 -

themedicinescompany.com - The Medicines Company (NASDAQ: MDCO) is scheduled to present at The Seventh Annual Needham Biotechnology and Medical Technology Conference on June 12th, at 3:00pm Eastern Time. A company overview and outlook will be provided in the presentation.

The session will be webcast with a link available at The Medicines Company's website: www.themedicinescompany.com.

MDCO-G

About The

Medicines Company

The Medicines Company (NASDAQ: MDCO) is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, a procedure to clear restricted blood flow in arteries around the heart. The Company also has two products in late-stage development, Cleviprex(TM) (clevidipine butyrate) injectable emulsion and cangrelor. The Company's website is www.themedicinescompany.com.

The Medicines Company
Robyn Brown, 973-656-1616
Vice President, Investor Relations
investor.relations@themedco.com


Disclaimer: (c) 2009 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Terms & Conditions | Privacy | About us | Contact PR-inside.com